March 18th 2024.
Heart failure is a serious condition that affects around 900,000 people in the UK. It is when the heart becomes weakened and is unable to pump enough blood to meet the body's needs. This can occur due to a variety of reasons, such as a heart attack, coronary heart disease, or heavy alcohol use. Unfortunately, there is no cure for heart failure, but a new and inexpensive test may soon be available to help identify those at the highest risk of dying from this condition.
The test focuses on a protein called neuropeptide Y (NPY), which is responsible for regulating brain activity, digestion, and is released by the heart in response to stress. A recent study published in the European Journal of Heart Failure found that patients with high levels of NPY were more likely to die from heart complications. In fact, those with elevated levels had a 50% higher risk of dying compared to those with lower levels.
The researchers behind this study hope that incorporating NPY testing alongside the currently used hormone, B-type natriuretic peptide, could help identify patients who would benefit from lifesaving implants. They plan to conduct larger trials in the future to further investigate this possibility.
Neil Herring, a professor of cardiovascular medicine and consultant cardiologist at the University of Oxford, expressed his excitement over the findings and the potential impact they could have on improving treatment for heart failure patients. He also mentioned that their research will continue to explore the role of NPY in identifying those who may benefit from lifesaving treatments.
It is estimated that the number of people living with heart failure in the UK will continue to rise due to an ageing population and improved survival rates after a heart attack. The British Health Foundation, which funded the study, emphasizes the importance of continuing to fund lifesaving research to improve the lives of those living with heart failure.
In conclusion, the discovery of the potential role of NPY in identifying high-risk heart failure patients is an exciting development that could greatly impact treatment in the future. With further research and testing, this simple and inexpensive blood test could be available within the next five years, providing hope for the increasing number of people living with this debilitating condition.
[This article has been trending online recently and has been generated with AI. Your feed is customized.]
[Generative AI is experimental.]
